Li L - Search Results

1

Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer.

Li L, Zhang J, Weng X, Wen G. Li L, et al. Tumour Biol. 2015 Jan;36(1):233-8. doi: 10.1007/s13277-014-2619-0. Epub 2014 Sep 19. Tumour Biol. 2015. PMID: 25234717

2

Novel microRNAs expression of patients with chemotherapy drug-resistant and chemotherapy-sensitive epithelial ovarian cancer.

Liu L, Zou J, Wang Q, Yin FQ, Zhang W, Li L. Liu L, et al. Among authors: li l. Tumour Biol. 2014 Aug;35(8):7713-7. doi: 10.1007/s13277-014-1970-5. Epub 2014 May 8. Tumour Biol. 2014. Retraction in: Tumour Biol. 2017 Apr 20. doi: 10.1007/s13277-017-5487-6 PMID: 24805828 Retracted.

3

Polygala tenuifolia polysaccharide PTP induced apoptosis in ovarian cancer cells via a mitochondrial pathway.

Zhang F, Song X, Li L, Wang J, Lin L, Li C, Li H, Lv Y, Jin Y, Liu Y, Hu Y, Xin T. Zhang F, et al. Among authors: li c, li h, li l. Tumour Biol. 2015 Apr;36(4):2913-9. doi: 10.1007/s13277-014-2921-x. Epub 2014 Dec 12. Tumour Biol. 2015. PMID: 25501282

4

Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.

Shen Y, Li L. Shen Y, et al. Among authors: li l. Tumour Biol. 2016 Nov;37(11):14765-14772. doi: 10.1007/s13277-016-5335-0. Epub 2016 Sep 15. Tumour Biol. 2016. PMID: 27629144

5

Polygala tenuifolia polysaccharide (PTP) inhibits cell proliferation by repressing Bmi-1 expression and downregulating telomerase activity.

Zhang F, Song X, Li L, Wang J, Lin L, Li C, Li H, Lv Y, Jin Y, Liu Y, Hu Y, Xin T. Zhang F, et al. Among authors: li c, li h, li l. Tumour Biol. 2015 Apr;36(4):2907-12. doi: 10.1007/s13277-014-2920-y. Epub 2014 Dec 13. Tumour Biol. 2015. PMID: 25501509

6

Overexpression of cysteine cathepsin L is a marker of invasion and metastasis in ovarian cancer.

Zhang W, Wang S, Wang Q, Yang Z, Pan Z, Li L. Zhang W, et al. Among authors: li l. Oncol Rep. 2014 Mar;31(3):1334-42. doi: 10.3892/or.2014.2967. Epub 2014 Jan 8. Oncol Rep. 2014. PMID: 24402045

7

Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.

Zhang W, Ling D, Tan J, Zhang J, Li L. Zhang W, et al. Among authors: li l. Oncol Rep. 2013 Feb;29(2):637-45. doi: 10.3892/or.2012.2148. Epub 2012 Nov 20. Oncol Rep. 2013. PMID: 23174953

8

Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.

Yin F, Liu X, Li D, Wang Q, Zhang W, Li L. Yin F, et al. Among authors: li d, li l. Int J Oncol. 2013 Apr;42(4):1305-16. doi: 10.3892/ijo.2013.1819. Epub 2013 Feb 8. Int J Oncol. 2013. PMID: 23404140

9

Tumor suppressor genes associated with drug resistance in ovarian cancer (review).

Yin F, Liu X, Li D, Wang Q, Zhang W, Li L. Yin F, et al. Among authors: li d, li l. Oncol Rep. 2013 Jul;30(1):3-10. doi: 10.3892/or.2013.2446. Epub 2013 May 9. Oncol Rep. 2013. PMID: 23660957 Review.

10

Overexpression of heparanase in ovarian cancer and its clinical significance.

Zhang W, Chan H, Wei L, Pan Z, Zhang J, Li L. Zhang W, et al. Among authors: li l. Oncol Rep. 2013 Nov;30(5):2279-87. doi: 10.3892/or.2013.2701. Epub 2013 Aug 27. Oncol Rep. 2013. PMID: 23982701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

100,032 results

Search Page

Filters